ATHE
Alterity·NASDAQ
--
--(--)
--
--(--)
ATHE Profile
Alterity Therapeutics Limited
An Australian biopharmaceutical company specializing in the treatment of neurological diseases
Biological Technology
11/11/1997
09/05/2002
NASDAQ Stock Exchange
9
06-30
Depository Receipts (Ordinary Shares)
Level 14, 350 Collins Street, Melbourne, VIC 3000, Australia
The company's business is to develop treatments for age-related diseases
Alterity Therapeutics Limited was incorporated under the laws of the Commonwealth of Australia on 11 November 1997. The company is developing first-in-class therapies for the treatment of neurodegenerative diseases. The company's lead drug candidate, ATH 434 (formerly PBT 434), is the first of a new generation of small molecules designed to block the accumulation and aggregation of α-synuclein. Alpha-synuclein, when aggregated in the brain, is a pathological marker of Parkinson's disease and is considered an important biological target for the treatment of these neurodegenerative diseases.
